AIP expression and imaging findings in somatotroph adenomas after pre-operative lanreotide therapy for acromegaly
Authors' conclusion
Higher expression of AIP after pre-operative SSA treatment was correlated with better hormone response to lanreotide.
Study context
- Population
- Patients with acromegaly (growth hormone (GH)-secreting macroadenomas) treated pre-operatively with lanreotide 120 mg Autogel monthly for 12 months16 with AIP-staining
- Participants
- 20 patients
- Exposure
- AIP-staining score vs lanreotide response and imaging
- Outcome
- Correlation of AIP protein expression with lanreotide response (IGF-1) and imaging characteristics
- Follow-up
- 12 months
Methodological detailssingle-arm lanreotide trial, immunohistochemical AIP-staining
- Single-arm lanreotide trial
- Immunohistochemical AIP-staining
Main finding
As reported in the abstract
AIP-staining score vs %-reduction in IGF-1
IGF-1 reduction at 12 months (mean 1.09 x upper limit of normal)
10 patients
Not biochemically controlled at 12 months (mean 2.51 x upper limit of normal)
6 patients
Required early surgery
3 patients
Observational data: associations, not effects.
Further findings
Tumour shrinkage · 12 months
- Mean tumour shrinkage; non-significantly greater with high vs low AIP-staining
- 25%
Original publication
AIP expression and imaging findings in somatotroph adenomas after pre-operative lanreotide therapy for acromegaly. Pituitary. Published 25 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →